• Vaccine Name: H65 + CAF01
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: H65 fusion protein that composed of EsxD, EsxC, EsxG, EsxH, EsxW, EsxV (Bertholet et al., 2010).
• esxD gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation(Blanco et al., 2021).
  • Detailed Gene Information: Click Here.
• esxC gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation(Blanco et al., 2021).
  • Detailed Gene Information: Click Here.
• esxG gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation(Blanco et al., 2021).
  • Detailed Gene Information: Click Here.
• esxH gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation(Blanco et al., 2021).
  • Detailed Gene Information: Click Here.
• esxV gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation(Blanco et al., 2021).
  • Detailed Gene Information: Click Here.
• esxW gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation(Blanco et al., 2021).
  • Detailed Gene Information: Click Here.
• Adjuvant: CAF01 vaccine adjuvant
  • Adjuvant name: CAF01 vaccine adjuvant
  • VO adjuvant ID: VO_0005483
  • Description: CAF01 was used as the adjuvant in this vaccine to enhance immune responses to the H65 fusion protein antigen (Bertholet et al., 2010).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: BALB/c
• Host age: 6 weeks old
• Host gender: female
• Vaccination Protocol: Mice were vaccinated subcutaneously with H65 formulated in CAF01, BCG, or a combination of BCG and H65. H65 and BCG+H65 groups received two booster doses of H65 formulated in CAF01 at 2-week intervals following primary vaccination(Blanco et al., 2021).
• Immune Response: Vaccination with H65 + CAF01, particularly in combination with BCG, induced enhanced protective immune responses resulting in significantly reduced Mycobacterium bovis bacterial burden in the lungs following challenge(Blanco et al., 2021).
• Challenge Protocol: Vaccinated mice were challenged by aerosol exposure with approximately 2000 CFU of virulent Mycobacterium bovis using an intrapulmonary aerosol chamber. Lung bacterial burden was assessed four weeks post-challenge by CFU enumeration(Blanco et al., 2021).
• Efficacy: The BCG + H65 prime-boost regimen significantly reduced lung bacterial loads compared with BCG or H65 alone, demonstrating improved protective efficacy against Mycobacterium bovis infection in mice(Blanco et al., 2021).
• Information about this animal model: Mouse Model for TB research